Preferred Label : Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978;
NCIt synonyms : CD19xCD3 T-cell Engager CLN-978; Anti-CD19/Anti-CD3 T-cell Engaging Bispecific Antibody CLN-978;
NCIt definition : A half-life extended T-cell engaging bispecific antibody comprised of a single chain
variable fragment (scFv) targeting the tumor-associated antigen (TAA) CD19, a scFv
targeting the T-cell surface antigen CD3, and a single-domain heavy chain variable
domain (VHH)-based antibody specific for human serum albumin (HSA), with potential
immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3
T-cell engaging bispecific antibody CLN-978 targets and binds to both CD19 antigen
expressed on tumor cells and CD3 antigen expressed on T-cells. This results in the
cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL)
response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell
surface antigen overexpressed in B-cell lineage malignancies. The HSA binding domain
prolongs the half-life of CLN-978.;
Molecule name : CLN 978; CLN-978;
NCI Metathesaurus CUI : CL1907352;
Origin ID : C200070;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
